                         SEQUENCE LISTING

<110>  OncoFluor, Inc.
       LUIKEN, George A.
 
<120>  METHOD FOR IMAGING AND TREATING ORGANS AND TISSUES

<130>  FLUOR1150-1WO

<150>  US 60/973,630
<151>  2007-09-19

<160>  12    

<170>  PatentIn version 3.4

<210>  1
<211>  5
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Synthetic construct

<400>  1

Gly Gly Gly Gly Ser 
1               5   


<210>  2
<211>  60
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Synthetic construct

<400>  2

Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly 
1               5                   10                  15      


Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly 
            20                  25                  30          


Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly 
        35                  40                  45              


Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser 
    50                  55                  60  


<210>  3
<211>  12
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Synthetic construct

<400>  3

Gly Lys Ser Ser Gly Ser Gly Ser Glu Ser Lys Ser 
1               5                   10          


<210>  4
<211>  14
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Synthetic construct

<400>  4

Gly Ser Thr Ser Gly Ser Gly Lys Ser Ser Glu Gly Lys Gly 
1               5                   10                  


<210>  5
<211>  18
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Synthetic construct

<400>  5

Gly Ser Thr Ser Gly Ser Gly Lys Ser Ser Glu Gly Ser Gly Ser Thr 
1               5                   10                  15      


Lys Gly 
        


<210>  6
<211>  14
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Synthetic construct

<400>  6

Gly Ser Thr Ser Gly Ser Gly Lys Ser Ser Glu Gly Lys Gly 
1               5                   10                  


<210>  7
<211>  18
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Synthetic construct

<400>  7

Gly Ser Thr Ser Gly Ser Gly Lys Pro Gly Ser Gly Glu Gly Ser Thr 
1               5                   10                  15      


Lys Gly 
        


<210>  8
<211>  14
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Synthetic construct

<400>  8

Glu Gly Lys Ser Ser Gly Ser Gly Ser Glu Ser Lys Glu Phe 
1               5                   10                  


<210>  9
<211>  5
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Synthetic construct

<400>  9

Ser Arg Ser Ser Gly 
1               5   


<210>  10
<211>  5
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Synthetic construct

<400>  10

Ser Gly Ser Ser Cys 
1               5   


<210>  11
<211>  28
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Synthetic construct

<400>  11

Ala Met Gly Arg Ser Gly Gly Gly Cys Ala Gly Asn Arg Val Gly Ser 
1               5                   10                  15      


Ser Leu Ser Cys Gly Gly Leu Asn Leu Gln Ala Met 
            20                  25              


<210>  12
<211>  60
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Synthetic construct

<400>  12

Ala Met Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly 
1               5                   10                  15      


Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser 
            20                  25                  30          


Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly 
        35                  40                  45              


Gly Gly Gly Ser Gly Gly Gly Gly Ser Gln Ala Met 
    50                  55                  60  


